Abstract
Mucolipidosis IV (MLIV) is an autosomal-recessive pediatric disease that leads to motor and cognitive deficits and loss of vision. It is caused by loss of function of the lysosomal channel transient receptor potential mucolipin-1 and is associated with an early pro-inflammatory brain phenotype, including increased cytokine expression. We thus hypothesized that peripheral blood cytokines would reflect inflammatory changes in the brain and would be linked to motor dysfunction. To test this, we collected plasma from MLIV patients and parental controls concomitantly with assessment of motor function using the Brief Assessment of Motor Function and Modified Ashworth scores. We found that MLIV patients had prominently increased cytokine levels compared to familial controls and identified profiles of cytokines correlated with motor dysfunction, including IFN-γ, IFN-α2, IL-17, IP-10. We found that IP-10 was a key differentiating factor separating MLIV cases from controls based on data from human plasma, mouse plasma, and mouse brain. Like MLIV patients, IL-17 and IP-10 were up-regulated in blood of symptomatic mice. Together, our data indicate that MLIV is characterized by increased blood cytokines, which are strongly related to underlying neurological and functional deficits in MLIV patients. Moreover, our data identify the interferon pro-inflammatory axis in both human and mouse signatures, suggesting an importance for interferon signaling in MLIV.
Competing Interest Statement
YG is an inventor on the IP (PCT/US2020/057839) filed through Mass General Brigham Corporation. YG received research support from the ML4 Foundation; YG and AM received research funding from the Million Dollars Bike Ride Program at UPenn Orphan Center for Rare Disease.
Clinical Trial
This study evaluated differences between a disease and control group, and was not a clinical trial.
Funding Statement
We thank the ML4 foundation, Dr. Rebecca Oberman and Randy Gold for providing research funding (Y.G) and help with blood samples collection. This work was also funded by the Upenn Orphan Disease Million Dollar Bike Run grant (to A.M. 2017D007934), NINDS/NIH (to A.M. 01K12NS098482-01) and startup funds from the Woodruff School of Mechanical Engineering at the Georgia Institute of Technology (L.B.W.). L.D.W. was supported in part by the National Institutes of Health Cell and Tissue Engineering Bio-technology Training Grant (T32-GM008433).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from legal guardians for participation in our approved natural history and biomarkers studies according to protocols approved by the Massachusetts General Hospital Institutional Review Board. Written informed consent or assent were obtained from patients if their neurological capacity allowed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data are available upon request.
